Condition: Uveal Melanoma · Sponsor: Institut Curie
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
This description comes directly from the study's public registry record.
Sophie Piperno-Neumann, MD · 01 44 32 46 72 · sophie.piperno-neumann@curie.fr
Marie-Emmanuelle Legrier, PhD · 01 56 24 56 49 · drci.promotion@curie.fr
Always discuss trial participation with your own doctor first.
| Institut Curie | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04424719